Artemisinin resistance in Plasmodium falciparum malaria.
暂无分享,去创建一个
K. Silamut | F. Nosten | Sue J Lee | N. Day | N. White | P. Ringwald | K. Chotivanich | D. Socheat | P. Singhasivanon | S. Yeung | F. Ariey | A. Dondorp | M. Imwong | J. Tarning | W. Hanpithakpong | N. Lindegårdh | P. Yi | D. Das | A. P. Phyo | K. Lwin. | Pharath Lim | T. Herdman | S. An | N. Lindegårdh | Warunee Hanpithakpong
[1] S. Meshnick,et al. Misclassification of drug failure in Plasmodium falciparum clinical trials in southeast Asia. , 2009, The Journal of infectious diseases.
[2] Stephane Proux,et al. Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment , 2009, PloS one.
[3] M. Fukuda,et al. Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.
[4] N. Day,et al. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[5] S. Meshnick,et al. Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border , 2008, Emerging infectious diseases.
[6] N. White,et al. Qinghaosu (Artemisinin): The Price of Success , 2008, Science.
[7] P. Newton,et al. Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. , 2008, The American journal of tropical medicine and hygiene.
[8] Anne Mills,et al. Access to artemisinin combination therapy for malaria in remote areas of Cambodia , 2008, Malaria Journal.
[9] Abdullah S Ali,et al. Impact of Artemisinin-Based Combination Therapy and Insecticide-Treated Nets on Malaria Burden in Zanzibar , 2007, PLoS medicine.
[10] N. Day,et al. Validation and application of a liquid chromatographic-mass spectrometric method for determination of artesunate in pharmaceutical samples. , 2007, Journal of pharmaceutical and biomedical analysis.
[11] S. Meshnick,et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. , 2007, The American journal of tropical medicine and hygiene.
[12] Pratap Singhasivanon,et al. How much fat is necessary to optimize lumefantrine oral bioavailability? , 2007, Tropical medicine & international health : TM & IH.
[13] P. Ringwald,et al. Efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia , 2006, Tropical medicine & international health : TM & IH.
[14] P. Ringwald,et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia , 2006, Tropical medicine & international health : TM & IH.
[15] F. Nosten,et al. Deployment of Early Diagnosis and Mefloquine- Artesunate Treatment of Falciparum Malaria in Thailand: The Tak Malaria Initiative , 2006, PLoS medicine.
[16] Eric Legrand,et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6 , 2005, The Lancet.
[17] B. Sharp,et al. Effect of Artemether-Lumefantrine Policy and Improved Vector Control on Malaria Burden in KwaZulu–Natal, South Africa , 2005, PLoS medicine.
[18] Arjen Dondorp,et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial , 2005, The Lancet.
[19] B. Sharp,et al. Intercontinental Spread of Pyrimethamine-Resistant Malaria , 2004, Science.
[20] François Nosten,et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number , 2004, The Lancet.
[21] S. Krishna,et al. Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.
[22] N. White,et al. Oral Artesunate Dose-Response Relationship in Acute Falciparum Malaria , 2002, Antimicrobial Agents and Chemotherapy.
[23] Newton Crjc.. NEUROLOGICAL ASPECTS OF TROPICAL DISEASE: Cerebral malaria , 2000 .
[24] C. Whitty,et al. A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. , 1999, The American journal of pathology.
[25] W. Jarra,et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[26] P. Rathod,et al. Variations in frequencies of drug resistance in Plasmodium falciparum. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[27] H. Webster,et al. The epidemiology of malaria in a Karen population on the western border of Thailand. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[28] D. Kyle,et al. Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. , 1996, Journal of Infectious Diseases.
[29] N. White,et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. , 1994, The Journal of infectious diseases.
[30] F. T. Ter Kuile,et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. , 1993, Experimental parasitology.
[31] J. Verdrager. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. , 1986, The Journal of tropical medicine and hygiene.
[32] H. Webster,et al. Antimalarial drug susceptibility testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method. , 1985, The American journal of tropical medicine and hygiene.
[33] C. Dolea,et al. World Health Organization , 1949, International Organization.